According to United Therapeutics's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 4.72809. At the end of 2023 the company had a P/S ratio of 4.44.
Year | P/S ratio | Change |
---|---|---|
2023 | 4.44 | -32.17% |
2022 | 6.55 | 13.37% |
2021 | 5.77 | 26.96% |
2020 | 4.55 | 70.46% |
2019 | 2.67 | -8.51% |
2018 | 2.92 | -21.3% |
2017 | 3.71 | -2.62% |
2016 | 3.81 | -22.17% |
2015 | 4.89 | 3.28% |
2014 | 4.73 | -7.2% |
2013 | 5.10 | 74.38% |
2012 | 2.93 | -21.12% |
2011 | 3.71 | -38.98% |
2010 | 6.08 | -21.25% |
2009 | 7.72 | 49.54% |
2008 | 5.16 | -49.88% |
2007 | 10.3 | 40.8% |
2006 | 7.31 | -47.4% |
2005 | 13.9 | 1.05% |
2004 | 13.8 | 50.09% |
2003 | 9.17 | -20.97% |
2002 | 11.6 | -68.42% |
2001 | 36.7 |
Company | P/S ratio | P/S ratio differencediff. | Country |
---|---|---|---|
Pfizer PFE | 2.46 | -48.02% | ๐บ๐ธ USA |
Eli Lilly LLY | 20.4 | 331.68% | ๐บ๐ธ USA |
Baxter BAX | 1.37 | -71.05% | ๐บ๐ธ USA |
Gilead Sciences GILD | 3.01 | -36.37% | ๐บ๐ธ USA |
Cardinal Health CAH | 0.1162 | -97.54% | ๐บ๐ธ USA |
GlaxoSmithKline GSK | 2.22 | -52.99% | ๐ฌ๐ง UK |
Cytokinetics
CYTK | 909 | 19,118.88% | ๐บ๐ธ USA |
Teva Pharmaceutical Industries TEVA | 0.9871 | -79.12% | ๐ฎ๐ฑ Israel |